Altimmune, Inc. (ALT) gains analyst support with an Overweight rating and $20 price target from Barclays. The company plans to use proceeds for Phase 3 MASH research. ALT focuses on peptide-based therapeutics for metabolic and liver diseases. Despite potential, other AI stocks may offer better upside. For more on AI stocks, see the link.

Read more at Yahoo Finance: Altimmune, Inc. (ALT) Gains Analyst Support Ahead of Phase 3 MASH Development